UK-based digital health and social care agency Healthcare Innovation Consortium is launching a new programme aimed at combating antimicrobial resistance (AMR) at Global Health 2023.
Launched in collaboration with Mecomed and Barts Life Sciences, Hill Dickinson LLP and Piper Health, the programme is targeting health technology innovators which can provide solutions to AMR, such as promoting optimal use of antibiotics in clinical practice and identification of antibiotic-resistant bacteria, with the aim of fast-tracking new technologies into the market.
The programme will be officially launched on the ABHI UK Pavilion at Global Health in Saudi Arabia later this month and is particularly focused on the UK and the Middle East.
The application window will be open until 1 December 2023, with the programme of support beginning late January 2024 and spanning two months.
Suzie Ali-Hassan, HIC chief partnerships officer, said: ’If we don’t address AMR, everyday operations like caesarean sections and hip replacements would be too dangerous to perform, and minor illnesses could become life-threatening. We want to amplify the UK’s contribution to containing and controlling AMR by bringing innovators together with researchers and industry experts to tackle this global priority.
‘We’re looking for diagnostic tools, smart systems, prescribing tools, screening devices, and other technologies that can support AMR prevention and management.’
HIC’s new AMR innovation programme aligns with other national programmes and initiatives that support the UK government’s aim to control AMR by 2040. The initiative will enable six applicants to receive comprehensive support to bring new solutions to market that can effectively target AMR: including: in-depth insights into the NHS and Middle East markets; engagement with academic and clinical experts in the field; and support to secure investment where applicable.
©2024 All rights reserved LaingBuisson 
 at Global Health 2023. ){kind=link}